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Background: Metabolic syndrome (MS) increases a risk of developing cardiovascular disease (CVD) and type 2
diabetes mellitus (T2DM). The Vitamin D Receptor gene (VDR) may be important for developing MS. The aim of
this study is to investigate the correlation between the VDR gene polymorphisms and MS in North China.
Methods: A case–control study included 391 participants with MS according to the MS diagnostic criteria of
International Diabetes Federation 2005 (IDF2005) and 400 controls was conducted on the basis of a cross sectional
study which was performed from 2008 to 2012 in Ningxia Hui Autonomous Region, China. Anthropometric data,
blood pressure and blood samples were collected in the field investigation. Blood biochemistry analyses were carried
out in the laboratory. Two single-nucleotide polymorphisms (SNPs) in the VDR gene, BsmI (rs1544410 A > G) and FokI
(rs 2228570 C > T), were genotyped.
Results: The difference in the occurrence of genotypes in BsmI between individuals with MS and the control group
was significant. Compared with genotype Bb/bb and allele b, genotype BB and allele B showed higher frequencies
in MS cases than controls, which suggested they were risk factors. In addition, the genotype BB carriers with MS
presented a higher waist circumference, while genotype FF for the FokI polymorphism was correlated with lower BMI
in subjects with MS.
Conclusion: Our study suggests that the VDR gene polymorphisms appear to be associated with MS in the Northern
Chinese population. Allele B and BB genotype for BsmI are risk factors for MS. The BsmI polymorphism seems to
influence waist circumference, while the FokI polymorphism influence BMI in subjects with MS.
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Metabolic syndrome (MS) includes a variety of meta-
bolic components in abnormal pathological state, which
contains abnormal plasma glucose, dyslipidemia, high
blood pressure, and high cholesterol [1]. Patients with
MS have a greater risk of developing cardiovascular dis-
ease (CVD) and type 2 diabetes mellitus (T2DM) [2-4].* Correspondence: zhabour@163.com
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unless otherwise stated.For the past few years, the prevalence of MS has been
on the rise in adults globally, increasing from about 20%
to 40% [5-8] in multiple groups of people, and is becoming
a serious global health burden. Although insulin resistance
[9] and central obesity [10] are considered to be its primary
etiological factors, genetics undoubtedly plays an important
role as well. In particular, genetic influence may be different
among various ethnic groups [11].
The Vitamin D receptor (VDR) is a member of the ster-
oid hormone receptor family that acts as a transcriptional
activator of many genes. The DNA polymorphisms thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in both restriction sites and dbSNP info): BsmI (rs1544410
A >G), FokI (rs 2228570 C > T), TaqI (rs731236 T > C),
and ApaI (rs 7975232 C > T). In past years, many studies
have found that these polymorphisms are related to
bone mineral density(BMD) [12], calcium metabolism
[13], tuberculosis, hepatitis [14] and cancer [15,16].
Additionally, some of these polymorphisms have been
recently identified to be associated with type 1 diabetes
[17], T2DM [18], and insulin secretion [19].
Although the molecular mechanisms of VDR in com-
ponents of MS remain unclear, a relationship between
25(OH)D3 and the disorders of MS has been previously
demonstrated [20-23]. Studies have also discussed VDR
gene polymorphisms for associations with the components
of MS, which suggest that two major VDR gene polymor-
phisms (BsmI and FokI) seemed to influence BMI, insulin
resistance, and serum HDL cholesterol [24,25]. However,
little is known about the role of VDR gene polymorphisms
in MS for Chinese population.
Therefore, we suppose the two single-nucleotide poly-
morphisms (SNPs), BsmI (rs1544410 A > G) and FokI (rs
2228570 C > T), of the VDR gene intricately affect the
development of MS. This study was designed to determine
the contribution of VDR polymorphisms to MS in a
population from North China.Materials and methods
Participants
A cross-sectional study was conducted from 2008 to 2012
in Guyuan County, Qingtongxia County and Pingluo
County, of Ningxia Hui Autonomous Region, China.
Stratified cluster sampling was applied to select two
villages (one Hui ethnic village and one Han ethnic
village) in each county, totaling six villages. During the
study period, 4614 subjects aged 24–75 were interviewed
with a questionnaire, followed by anthropometric measure-
ments (height, weight, waist circumference), and blood
pressure determination. Pregnant or breastfeeding women,
patients with severe mental disease and other serious illness
were excluded from the study. The subjects enrolled did
not report to have chronic viral infection, cold or flu, acute
respiratory infection, or any type of surgery in the week
preceding the study. Meanwhile, 2615 participants had
blood drawn via venipuncture for laboratory measure-
ments, and finally 1169 blood samples were selected for
genotyping by mechanical sampling (k = 1). Based on
diagnostic criteria (International Diabetes Federation
IDF-2005), 391 cases with MS and 400 controls were
selected from the same population to conduct the
case–control study. The study protocol had been
approved by the Medical Ethics Review Committee of
Ningxia Medical University. All participants signed theconsents on enrollment after they received written and
verbal information about the study.
All participants were interviewed by trained persons
with a standard closed-ended questionnaire. The con-
tents of the questionnaire included general demographic
characteristics, blood pressure, blood lipid, blood sugar,
smoking, physical activity status, drinking and related
diseases (including hypertension, coronary heart disease,
stroke and diabetes medical history and family history,
individual treatment, etc.).Anthropometric measurements and blood pressure
Standing height was measured using a portable ruler.
Body weight was also measured using a weight scale
(Omron, China). All measurements were performed by
well-trained investigators. The reading of measurements
was accurate within 0.1 cm or 0.1 kg, and the average of
the two collected measures was recorded for further
analysis. Body mass index (BMI) was calculated as kg/m2.
Obesity was defined as BMI ≥ 30. Arterial blood pressure
was measured three times in sitting position using an elec-
tronic sphygmomanometer (Omron-HEM 7301-IT, China).
All participants were at rest for at least 30 minutes before
the measurement was collected. Patients with average
blood pressures ≥140/90 mmHg or taking antihyper-
tensive medication in 2 weeks were classified as being
hypertensive.Blood biochemistry analyses
Blood samples were drawn from the antecubital vein at
the hours of 6 to 8 AM, after at least 10 hours of fasting
and avoidance of alcohol. Two sets of fasting blood
samples were collected separately from each subject in
sodium fluoride potassium oxalate tubes (for glucose)
and lithium heparin vacuum tubes (for lipids).The latter
collections were then centrifuged and kept at −80°C
until analysis. Fasting glucose was immediately determined
by One Touch Ultra 2 (LifeScan, USA). Serum levels of
HDL- cholesterol, LDL- cholesterol, and triglycerides
were measured by enzymatic assay (CHOD-PAP, Roche
Diagnostics GmbH). All analyses were carried out through
an automatic biochemical analyzer (COBASE 501, Roche
Diagnostics GmbH). Subjects were further divided into
two groups, cases with MS and controls without MS,
according to the IDF definition. For a subject to be
defined as having MS, they must have: Central obesity
(waist circumference ≥ 90 cm in males, ≥ 80 cm in
females, or BMI is >30 kg/m2) along with any two of
the following four factors: triglycerides ≥ 150 mg/dL
(1.7 mmol/L); HDL-cholesterol < 40 mg/dl (1.03 mmol/L)
in males, < 50 mg/dL(1.29 mmol/L) in females; blood
pressure, systolic BP ≥ 130 or diastolic BP ≥ 85 mmHg;
fasting glucose ≥5.6 mmol/L (100 mg/dl) [1].
Table 1 Population Characteristics and components of MS
MS Control P-value
Male/Female, n 99/292 100/300 0.917
Age 53.37 ± 10.99 53.73 ± 11.08 0.997
Height(cm) 159.09 ± 8.11 157.73 ± 7.34 0.018
Weight(kg) 66.19 ± 10.15 56.09 ± 7.90 <0.001
BMI 26.09 ± 2.97 22.53 ± 2.72 <0.001
WC(cm) 89.70 ± 6.63 79.11 ± 7.47 <0.001
BPS(mmHg) 136.88 ± 20.38 124.87 ± 18.29 <0.001
BPD(mmHg) 84.13 ± 11.55 77.19 ± 11.01 <0.001
FBG(mmol/L) 6.15 ± 1.31 5.58 ± 0.83 <0.001
TG(mmol/L) 2.07 ± 1.19 1.30 ± 1.16 <0.001
HDL-C(mmol/L) 1.28 ± 0.38 1.48 ± 0.34 <0.001
WC, Waist circumference; BPS, Systolic blood pressure; BPD, Diastolic blood
pressure; FBG, fasting blood-glucose; TG, triglycerides; HDL-C, HDL- cholesterol.
Table 2 Hardy-Weinberg equilibrium of control group
Genotype Predictive value Observed value χ2 P-value
BsmI CC 328.52 328 0.092 0.762
CT 67.97 69
TT 3.52 3
FokI AA 84.39 80 0.783 0.376
AG 198.22 207
GG 116.39 112
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Genomic DNA was extracted from the whole blood with
the SE Blood DNA Kit (OMEGA, USA). After extraction,
30 samples of the extracted material were randomly
selected for validation by agarose gel electrophoresis.
SNP genotyping of BsmI and FokI in the VDR gene was
performed using a technology known as SNPscan™
[26-28](Genesky Biotechnologies, China). SNPscan™ is
a patent technology and developed on double ligation
and multiplex fluorescence PCR with high genotyping
accuracy (>99.9%) and call rate (>98%). Specifically,
highly multiple ligation products in different length
were generated on account of high specificity of the
ligase reaction. Meanwhile, the ligation probes and
templates were further lengthened through double
ligation. With blue fluorescent dye modified universal
primers, ligation products were amplified by Thermal
Cycler (ABI, USA) and then detected through fluorescent
capillary electrophoresis. Finally, GeneMapper (Life Tech-
nologies) software was used to read the data.
Statistical analysis
Statistical analysis was conducted using SPSS statistical
software (version 14.0 SPSS Corp, College Station, TX) and
descriptive data were presented by mean and standard devi-
ation. The Kolmogorov-Smirnov test was used to analyze
normality of the distribution of each variable. Comparisons
between any two groups were performed using independ-
ent t-tests. Chi-square analysis was applied to examine the
variation of sex, genotype and gene frequency in different
MS groups. Chi-square analysis was also used to test
Hardy–Weinberg equilibrium (HWE) for the genotypes in
all groups of subjects. ANOVA analysis was used to analyze
clinical variables in different genotypes. Odds ratios (ORs)
and their 95% confidence interval (CI) were computed for
the risk alleles from logistic regression analysis. Statistical
significance was set at P < 0.05.
Results
General characteristics and components of MS
Characteristics of the subjects with and without MS are
shown in Table 1. In our study, the mean age of the 391
participants with MS was 53 (±11) years, and the mean
age of 400 controls was 53 (±11) years. Compared with
the controls, BMI, waist circumference, blood pressure,
fasting glucose, and triglycerides were significantly higher
in individuals with MS, while HDL cholesterol was lower.
Both VDR BsmI and FokI genotypic distributions in
controls were in Hardy-Weinberg equilibrium (P, 0.762
and 0.376, respectively) (Table 2).
The distribution of VDR BsmI and FokI polymorphisms
As shown in Table 3, both genotypic and allelic frequencies
of VDR BsmI and FokI polymorphisms were presented forparticipants with or without MS. Genotypes of BsmI and
FokI are normally expressed as dominant homozygous
genotype “BB, FF”, heterozygous genotype “Bb, Ff”, and
recessive homozygous genotype “bb, ff”. There were dif-
ferences in genotypes and gene frequencies of VDR
BsmI between the MS cases and controls, with P-values
of 0.011 and 0.03 respectively. Frequency of genotype
BB and Bb was significantly different between individuals
with MS and without MS, after comparing all of the three
genotypes with each other (χ2 = 7.022, P = 0.008). How-
ever, there was no difference in FokI polymorphism.
VDR polymorphisms and MS risk
The difference in the occurrence of the genotypes in
BsmI between individuals with MS and the control
group was significant (Ptrend = 0.02). The frequencies of
genotype BB and combined Bb/bb in individuals with
MS were 89% and 11% respectively, in the control group
were 82% and 18% respectively, which suggested that the
genotype BB was a risk factor (P = 0.006; OR = 1.771; 95%
CI, 1.179-2.661). Compared with genotype BB, genotype Bb
was likely to be a protective factor (P = 0.009; OR = 0.575;
95% CI, 0.381-0.869). The incidences of B and b alleles for
the BsmI polymorphism in the two group were statistically
significant (allele B vs. b; P = 0.005), which indicated allele b
Table 3 Genotypes and gene frequencies
BsmI FokI
BB Bb bb B b FF Ff ff F f
MS, n 347 42 1 736 44 75 184 132 334 448
Control, n 328 69 3 725 75 80 207 112 367 431
χ2 – 9.016 3.073 1.720
P-value 0.011* 0.03 0.215 0.19
*Fisher's Exact Test; BB/FF normally show dominant homozygous
genotype; Bb/Ff show heterozygous genotype; bb/ff show recessive
homozygous genotype.
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cant evidence to be risk factors or protective factors to FokI
polymorphism in individuals with MS (Table 4).
Moreover, the genotypes of BsmI and FokI were com-
bined and generated as 9 new genotypes like BBFF to
analyze the cumulative effect of the polymorphisms, as
shown in Table 4. But there were no significant differ-
ences in the risk of MS (Ptrend = 0.187).Table 4 FokI and BsmI polymorphisms and MS risk
Genotype MS n(%) Control n(%) P-value OR 95% CI
BsmIa
BB(CC) 347(89.0) 328(82.0) 1
Bb(CT) 42(10.7) 69(17.3) 0.009 0.575 0.381-0.869
bb(TT) 1(0.3) 3(0.7) 0.318 0.315 0.033-3.044
Bb + bb 43 72 1
BB 347 328 0.006 1.771 1.179-2.661
B 736(94.4) 725(90.6) 1
b 44(5.6) 75(9.4) 0.005 0.578 0.393-0.850
FokIb
FF(AA) 75(19.2) 80(20.0) 1
Ff(AG) 184(47.1) 207(58.9) 0.779 0.948 0.653-1.376
ff(GG) 132(33.7) 112(28.1) 0.266 1.257 0.840-1.882
Ff + ff 316 319 1
FF 75 80 0.759 0.946 0.666-1.345
F 334(42.7) 367(46.0) 1
f 448(57.3) 431(54.0) 0.190 1.142 0.936-1.393
BBFFc 69 68 1
BBFf 164 174 0.761 0.929 0.624-1.382
BBff 114 85 0.211 1.322 0.854-2.046
BbFF 5 11 0.156 0.448 0.148-1.358
BbFf 19 32 0.111 0.585 0.303-1.131
Bbff 18 26 0.276 0.682 0.343-1.358
bbFF 0 1 1.000 0.000 0.000
bbFf 1 1 0.992 0.986 0.060-16.077
Bbff 0 1 1.000 0.000 0.000
aPtrend = 0.02; bPtrend = 0.216; cPtrend = 0.187;BB/FF normally show
dominant homozygous genotype; Bb/Ff show heterozygous genotype;
bb/ff show recessive homozygous genotype.The associations of VDR gene polymorphisms with the
components of MS
Table 5 presented the distribution of some clinical vari-
ables according to the genotypes observed in individuals
with MS and without MS. Because of the limited frequen-
cies of genotype bb in the VDR BsmI polymorphism, we
combined Bb and bb genotype as a group. For the VDR
BsmI variant, individuals with MS carrying BB genotype
presented a higher waist circumference than individuals
with Bb + bb genotype, whilst genotype BB was associated
with higher waist circumference and BMI in individuals
without MS than seen in others. Additionally, the presence
of FF genotype for the FokI polymorphism was associated
with lower BMI than that with Ff/ff genotype in individuals
with MS. In addition, to the individuals without MS, higher
systolic blood pressure was seen in subjects with Ff geno-
type than that with ff genotype, and subjects with genotype
FF/Ff presented a higher diastolic blood pressure than
individuals with ff genotype. Moreover, the values of the
remaining variables were very similar among all subjects
for both VDR BsmI and FokI polymorphisms.
Discussion
The results showed that VDR polymorphisms may influ-
ence the emergence of MS. The VDR BsmI (rs1544410
A > G) polymorphism appeared to associate with MS.
Specifically, allele B and genotype of BB in BsmI were
associated with MS, while allele b and genotype Bb
seemed to play a protective role. The role of genotype
bb was unclear, because of its limited frequency. When
discussed VDR gene polymorphisms with the compo-
nents of MS, we found the genotype BB carriers with
MS presented a higher waist circumference. In addition,
genotype FF for the VDR FokI (rs2228570 C > T) poly-
morphism was correlated with lower BMI in MS. Our
findings were different with previous researches which
demonstrated the VDR FokI polymorphism was related
with triglycerides and HDL-cholesterol levels [25].
A few studies have demonstrated that VDR polymor-
phisms were related to obesity, diabetes, insulin sensitivity
and insulin secretion [17,19,29]. VDR BsmI and FokI poly-
morphisms have been previously reported to be associated
with anthropometric and biochemical parameters describ-
ing MS. Trzmiel et al. (2008) found that VDR BsmI poly-
morphism seemed to influence BMI, while the FokI VDR
polymorphism appeared to affect insulin sensitivity and
serum HDL cholesterol in men [24]. However, Lwow et al.
(2008) indicated that VDR BsmI polymorphism did not
seem to predispose postmenopausal women to obesity
and insulin resistance, but the genotype BB was connected
with dyslipidemia [30]. Frey et al. (2003) did not find
evidence for the association of VDR polymorphisms
with glycemia either [31]. Results of these study seemed
to conflict with the pleiotropic effect of the VDR gene
Table 5 FokI and BsmI polymorphisms and MS components
BsmI (rs1544410 A > G) P FokI (rs 2228570 C > T) P
BB Bb + bb FF Ff ff
MS BMI 26.1 ± 3.1 25.7 ± 2.2 0.396 25.1 ± 2.5a 26.3 ± 3.1 26.4 ± 2.9 0.005
WC(cm) 90 ± 6.6 87.6 ± 6.3 0.025 88.7 ± 5.5 89.7 ± 7 90 ± 6.6 0.284
BPS(mmHg) 136.4 ± 19.8 141.9 ± 22.7 0.096 135.9 ± 20 137.5 ± 20.6 136.6 ± 20.4 0.829
BPD(mmHg) 84.1 ± 11.4 85 ± 12.5 0.625 84 ± 11.8 84.8 ± 11.3 83.2 ± 11.8 0.438
FBG(mmol/L) 6.1 ± 1.2 6.4 ± 2.2 0.163 6.2 ± 1.6 6.1 ± 1 6.2 ± 1.5 0.496
TG(mmol/L) 2.1 ± 1.2 2 ± 1.2 0.788 2.1 ± 0.9 2.1 ± 1.3 2 ± 1.2 0.821
HDL-C(mmol/L) 1.3 ± 0.4 1.4 ± 0.3 0.177 1.2 ± 0.3 1.3 ± 0.3 1.3 ± 0.5 0.077
Control BMI 22.7 ± 2.8 22 ± 2.4 0.030 22.5 ± 2.9 22.5 ± 2.6 22.5 ± 2.8 0.995
WC(cm) 79.7 ± 7.6 76.3 ± 6.1 0.000 78.7 ± 8 79.2 ± 6.5 79.2 ± 8.7 0.849
BPS(mmHg) 124.9 ± 18.3 124.9 ± 18.3 0.985 124.9 ± 18.6 126.8 ± 19.3b 121.5 ± 15.6 0.045
BPD(mmHg) 77.2 ± 11.1 77.1 ± 10.8 0.939 78.2 ± 10.5 78.1 ± 11.8 74.9 ± 9.4a 0.031
FBG(mmol/L) 5.6 ± 0.9 5.6 ± 0.5 0.727 5.5 ± 0.8 5.7 ± 1 5.5 ± 0.5 0.118
TG(mmol/L) 1.3 ± 1.2 1.2 ± 0.6 0.254 1.3 ± 0.6 1.3 ± 1.5 1.2 ± 0.6 0.789
HDL-C(mmol/L) 1.5 ± 0.3 1.5 ± 0.3 0.227 1.4 ± 0.3 1.5 ± 0.3 1.5 ± 0.3 0.596
asignificant for the genotype Ff/ff; bsignificant for the genotype ff.
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other populations [32]. Moreover, interactions in circulating
glucose, triglyceride, cholesterol and insulin levels were
not well explained [33,34]. For this reason, whether these
differences come from ethnic variations or interactions in
components of MS still needs further exploration, and we
should not focus on the disorders in MS separately.
The VDR gene is not a main influencing factor to the
variability of circulating levels of vitamin D, according to
genome-wide association (GWA) studies [17,35,36]. How-
ever, it is clear that the VDR gene plays a primary role in
the pleiotropic actions of 1,25(OH)2D3 [37] and in insulin
secretion [19,38]. Serum 25-hydroxyvitamin D levels is
inversely related to percentage body fat content in healthy
women [20] and incident hypertension [21]. Furthermore,
McKeown et al. (2011) found that the predicted 25-
hydroxyvitamin D score might be an important deter-
minant for change in fasting plasma glucose concentration
in the Framingham offspring study [22]. Unfortunately,
our study did not include serum 25-hydroxyvitamin D,
but we could assume that serum 25-hydroxyvitamin D is
the focus leading metabolic disorders if the interactions
we discussed above were taken into consideration.
Conclusion
This study revealed a significant association of VDR
BsmI polymorphism with MS in the Northern Chinese
population. Allele B and genotype BB for BsmI are risk
factors for MS. The BsmI polymorphism seemed to influ-
ence waist circumference, while the FokI polymorphism
influence BMI in subjects with MS. Thus, we propose that
the BsmI and FokI polymorphisms of VDR are potentialprognostic variables which may predict the risk of devel-
oping MS. Even so, further examination should be carried
out on large population. Also, genome wide association
studies are still needed to evaluate the direct effect of
these polymorphisms on MS.
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